Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Boston Medical Group vs TeleCareSpot

Boston Medical Group
Graded #279

Lower grade

vs+5.800000000000004
TeleCareSpot
Graded #160

Higher grade

The verdict

TeleCareSpot takes it — 67.7/100 to 61.9/100.

TeleCareSpot grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. TeleCareSpot is a telehealth weight-loss platform offering doctor-prescribed compounded GLP-1s with flat, all-inclusive monthly pricing: compounded semaglutide at $299/month and tirzepatide at $399/month…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueBoston Medical Group +11
54
43
Dose & formulationTeleCareSpot +31
52
83
Clinical oversightBoston Medical Group +6
89
83
Labs & monitoringBoston Medical Group +1
53
52
FulfillmentTeleCareSpot +27
65
92
Contract termsTeleCareSpot +6
55
61
Boston Medical Group · left barTeleCareSpot · right bar

The numbers

MetricBoston Medical GroupTeleCareSpot
WeighScore61.9/10067.7/100
GradeCC
Scorecard rank#279#160
Semaglutide$199/mo (starting strength, rising with dose, compounded)$299/mo (all doses, plus a separate fee, compounded)
TirzepatideNot disclosed$399/mo
Coverage7 states48 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
Boston Medical Group

Graded #279 · C

Strengths

  • An established medical group with a defined 12-week programme rather than an open-ended subscription
  • The price range and the 12-week total are both published, once you reach the costs page
  • Semaglutide is prescribed and dispensed under a compounded pathway with clinician oversight

Where it loses points

  • The published rate is a range by dose strength, $199 to $299, so the figure quoted is the floor rather than what a titrated patient pays
  • The 12-week programme totals $699 including a telemedicine platform fee that is never itemised — about $233/mo all-in, not $199
  • The weight-loss landing page carries no price at all; the numbers are two pages deeper, in the FAQ and the costs page
  • Semaglutide and tirzepatide are not priced separately — one range covers the whole programme
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products
TeleCareSpot

Graded #160 · C

Strengths

  • Flat, all-inclusive monthly pricing with no hidden fees — compounded semaglutide $299/month and tirzepatide $399/month, all doses included
  • Verifiable LegitScript certification (seal ID 45936855) plus HIPAA compliance and licensed US physicians
  • Multiple options: compounded semaglutide, tirzepatide, oral tirzepatide, and phentermine
  • DNA-calibrated dosing option that tailors the GLP-1 dose to how you metabolize it
  • Broad coverage in 47 states and DC, with free shipping and cancel-anytime plans

Where it loses points

  • Compounded medications are not FDA-approved — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • Not available in Alaska, Mississippi, or New Jersey
  • The compounding pharmacy partner is not named
  • A separate weight-loss consultation fee applies (credited toward your medication package if approved)
  • Trustpilot rating and review counts (4.9, 14,000+) are self-stated on the site

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard